GURU.Markets stock price, segment price, and overall market index valuation
The company's share price XFOR
X4 Pharmaceuticals is a biotech company focused on treating rare immune diseases. Its stock price is highly volatile and depends on clinical trial results and regulatory decisions regarding its drugs.
Share prices of companies in the market segment - Pharma immune
X4 Pharmaceuticals is a biotechnology company developing drugs to treat rare immunodeficiency diseases by blocking the abnormal activity of the CXCR4 protein. We have classified it in the "Pharma-Immune" segment. The chart below shows the overall dynamics in the immunology sector, where targeted therapies are opening up new treatment options.
Broad Market Index - GURU.Markets
X4 Pharmaceuticals is a biopharmaceutical company developing drugs to treat rare immunodeficiency diseases and oncology. Its focus on this niche makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how X4 compares to it.
Change in the price of a company, segment, and market as a whole per day
XFOR - Daily change in the company's share price XFOR
X4 Pharmaceuticals' daily share price fluctuations reflect the extreme volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its drugs for rare immune diseases.
Daily change in the price of a set of shares in a market segment - Pharma immune
X4 Pharmaceuticals, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with XFOR, which focuses on rare disease treatments, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
X4 Pharmaceuticals develops drugs to treat rare immune diseases. This is a niche but important area of medicine. The company's success depends on clinical data and regulatory approval. Its stock price fluctuations reflect the hopes of patients with rare diagnoses, adding a highly specialized scientific rhythm to the overall market pulse visible on the chart.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization XFOR
X4 Pharmaceuticals' year-to-date performance is a story about developing drugs for rare immune diseases. Its 12-month market cap depends entirely on the progress of its lead candidate in clinical trials. Successful FDA approval could transform the company into a commercial company and fundamentally change its valuation.
Annual dynamics of market capitalization of the market segment - Pharma immune
X4 Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing drugs for the treatment of rare immunological diseases. This chart shows how its commercialization success, clinical trial results, and focus on this narrow but important niche are impacting its performance in the pharmaceutical sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
X4 Pharmaceuticals is a biopharmaceutical company whose stock performance is driven by the commercialization of its products and progress in research. The company's business is not dependent on economic cycles. This chart reflects biotech events, not macroeconomic data.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization XFOR
X4 Pharmaceuticals is a biopharmaceutical company focused on rare immune diseases. Its monthly performance is driven by clinical and regulatory events. News of the approval of its first drug and progress in other clinical programs are the main drivers.
Monthly dynamics of market capitalization of the market segment - Pharma immune
X4 Pharmaceuticals develops drugs to treat rare immune diseases and oncology. Its lead candidate targets WHIM syndrome. The company's success depends on regulatory approval and commercial launch. The biotech sector's performance reflects investor interest in orphan diseases, which is an important backdrop for assessing X4's niche strategy.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
X4 Pharmaceuticals develops drugs to treat rare immune diseases. The company's shares, focused on orphan diseases, exist in their own information space. Their price is determined by progress in clinical trials and FDA decisions. There is virtually no connection to overall market trends, as the chart demonstrates.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization XFOR
X4 Pharmaceuticals, a biotech focused on rare immune diseases, exhibits high volatility. Weekly stock performance hinges on news about clinical trials and regulatory decisions, each of which is crucial.
Weekly dynamics of market capitalization of the market segment - Pharma immune
X4 Pharmaceuticals develops drugs to treat rare immune and oncological diseases. Its focus on orphan diseases can lead to strong stock movements. The chart will help separate its own data-driven dynamics from the broader swings in its sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
X4 Pharmaceuticals is a clinical-stage biotech company. Its shares exist in a world of their own, where research data is king. The chart clearly demonstrates that X4's performance is almost uncorrelated with the market.
Market capitalization of the company, segment and market as a whole
XFOR - Market capitalization of the company XFOR
X4 Pharmaceuticals chart is a financial map of the fight against rare immune diseases. The company's market cap reflects the hopes for its drug for the treatment of WHIM syndrome and other immune disorders. Its dynamics are a barometer of progress in clinical trials and the belief that its approach will help patients with these devastating conditions.
XFOR - Share of the company's market capitalization XFOR within the market segment - Pharma immune
X4 Pharmaceuticals's immunology market share is focused on treating rare diseases associated with immune system dysfunction. Its market share is driven by the potential of its drugs, which target the specific CXCR4 signaling pathway, to help patients with limited treatment options.
Market capitalization of the market segment - Pharma immune
X4 Pharmaceuticals is a biotech company focused on treating rare immune diseases. The chart below shows the overall market capitalization of this cutting-edge sector. Its dynamics reflect investor expectations for the development of new, highly effective drugs.
Market capitalization of all companies included in a broad market index - GURU.Markets
X4 Pharmaceuticals develops drugs to treat rare immune and oncological diseases associated with the CXCR4 pathway. Its market capitalization is a bet on this scientific approach. The chart below shows the economic weight of companies working with rare genetic targets.
Book value capitalization of the company, segment and market as a whole
XFOR - Book value capitalization of the company XFOR
X4 Pharmaceuticals' book value represents its capital for R&D and commercialization. The chart below shows the financial resources needed to bring its first drug for rare immune diseases to market. This is a story of transitioning from research to sales.
XFOR - Share of the company's book capitalization XFOR within the market segment - Pharma immune
X4 Pharmaceuticals is a biotech company focused on rare immune diseases. Its core capital is intellectual property. The share of physical assets will reflect its research-focused model, where its key assets are its high-tech laboratories.
Market segment balance sheet capitalization - Pharma immune
X4 Pharmaceuticals is a commercial biopharmaceutical company. Its business model is "light," focusing on drug development and commercialization while outsourcing manufacturing. The chart will show whether this structure is typical for the industry as a whole.
Book value of all companies included in the broad market index - GURU.Markets
X4 Pharmaceuticals' assets are capital focused on developing drugs to treat rare immune and oncological diseases by inhibiting the CXCR4 receptor. The book value chart shows the amount of resources devoted to this specific therapeutic target.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - XFOR
X4 Pharmaceuticals develops drugs to treat rare immune diseases and oncology. Its market capitalization is based on the potential of its lead drug. The chart shows how investors evaluate the clinical data and commercial prospects of this niche drug.
Market to book capitalization ratio in a market segment - Pharma immune
X4 Pharmaceuticals is a biotech company developing drugs to treat rare immune diseases. Its value depends almost entirely on the success of its clinical programs. The chart shows the huge premium investors are paying for the hope of approval of its drugs.
Market to book capitalization ratio for the market as a whole
X4 Pharmaceuticals is a biotech company developing drugs to treat rare immune diseases and oncology. This chart shows how the market values a company with an approved niche drug. Its market capitalization is based on the drug's commercial potential and investor confidence in its scientific platform for developing new products.
Debts of the company, segment and market as a whole
XFOR - Company debts XFOR
X4 Pharmaceuticals is a biopharmaceutical company focused on treating rare diseases related to the immune system. Debt instruments are used by the company in its pre-commercialization phase to finance the development of a sales team and marketing infrastructure.
Market segment debts - Pharma immune
X4 Pharmaceuticals is a biopharmaceutical company specializing in the treatment of rare diseases related to the immune system. Their drugs target a specific signaling pathway. The chart illustrates the financial norms for the biotech sector, where companies like X4 raise significant capital to fund their highly specialized and expensive clinical programs.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio XFOR
X4 Pharmaceuticals develops drugs to treat rare immune and oncological diseases. This focus on orphan diseases requires targeted yet significant investments in R&D. This chart shows the proportion of debt funding for these developments. This helps investors assess the company's financial risks in bringing its drug to market.
Market segment debt to market segment book capitalization - Pharma immune
X4 Pharmaceuticals' development of drugs for rare immune diseases targets small patient groups. This chart illustrates how the biotech sector funds orphan drugs. It allows one to assess the company's financial model and its dependence on success in this narrow but important niche compared to mass-market drugmakers.
Debt to book value of all companies in the market
X4 Pharmaceuticals develops drugs to treat rare immune and oncological diseases. Their focus on orphan diseases requires targeted but significant funding. The chart shows how their debt-based strategy for bringing niche drugs to market compares to the overall market.
P/E of the company, segment and market as a whole
P/E - XFOR
This metric for X4 Pharmaceuticals, a biopharmaceutical company focused on treating rare immune diseases, reflects investor confidence. The company's value is determined not by current profits, but by the potential of its drugs, which target a specific molecular pathway associated with immune cell movement.
P/E of the market segment - Pharma immune
This metric represents the average valuation for the biotech sector in which X4 Pharmaceuticals operates. In this industry, filled with research-stage companies, the average earnings estimate is often uninformative. However, it does reflect the overall level of investor optimism regarding treatments for rare immune diseases.
P/E of the market as a whole
X4 Pharmaceuticals develops drugs to treat rare diseases associated with immune system dysfunction. Its lead candidate targets chronic neutropenia. This chart shows biotech sentiment. It helps understand how the market views the company's potential in orphan diseases and how news about clinical trials and regulatory decisions impact its valuation.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company XFOR
X4 Pharmaceuticals is a biotech company developing treatments for rare immune and oncological diseases associated with the CXCR4 signaling pathway. Its future depends on the success of its lead drug for the treatment of WHIM syndrome. This chart reflects investor expectations regarding the potential of its targeted therapy and commercial prospects in the rare disease field.
%20P%2FE%20XFOR&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-XFOR&v=1772545619752 "Chart of the company's future (projected) P/E XFOR")
Future (projected) P/E of the market segment - Pharma immune
X4 Pharmaceuticals is a biotech company developing drugs to treat rare diseases associated with immune system dysfunction. Its approach is based on blocking a specific receptor. This chart reflects expectations for the biotech sector, helping to assess how the market views this orphan-focused strategy.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772545619765 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
X4 Pharmaceuticals is a biopharmaceutical company developing drugs to treat rare immune diseases and oncology. Their approach is aimed at modulating the chemokine receptor CXCR4. This chart of general expectations illustrates investor sentiment toward the biotech company. Market optimism and risk appetite are essential for funding drug development for patients with limited treatment options.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772545619817 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit XFOR
X4 Pharmaceuticals is a biopharmaceutical company developing drugs to treat rare immune diseases and oncology. This chart shows the company's financial position as it moves toward commercialization. Profit is contingent on the approval and successful launch of its first drug, designed to treat a rare immunodeficiency.
Profit of companies in the market segment - Pharma immune
Aeries Technology is a company providing IT outsourcing and consulting services. Its profitability depends on corporate technology spending and competition in the IT services market. This chart reflects the stable demand for digitalization that supports the sector, but pricing pressure and the need to retain qualified specialists impact profitability.
Overall market profit
X4 Pharmaceuticals develops drugs to treat rare diseases associated with immune system dysfunction. The company is focusing on a new therapeutic target. Its success depends entirely on the results of clinical trials and regulatory approval, which could offer new treatment options for patients with rare diagnoses.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company XFOR
X4 Pharmaceuticals is a biotech company developing drugs to treat rare immunodeficiency diseases. Its revenue forecast depends on the approval and commercial success of its lead drug candidate. This chart shows analyst expectations for the orphan disease market and the potential of X4's developments.
%20profit%20of%20the%20company%20XFOR&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-XFOR&v=1772545620154 "Graph of future (projected) profit of the company XFOR")
Future (predicted) profit of companies in the market segment - Pharma immune
X4 Pharmaceuticals develops drugs to treat rare diseases associated with dysfunction of the CXCR4 chemokine receptor, including congenital immunodeficiencies. This chart shows profitability projections for the biotech sector. It reflects the potential and complexity of developing drugs for rare genetic diseases with a clearly defined target.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772545620419 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
X4 Pharmaceuticals develops treatments for rare diseases related to the immune system. The company's success depends on clinical data and regulatory approval. This graph of overall revenue projections is important because it forms the investment backdrop and influences the valuation of biotech companies when raising capital or finding partners.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772545620463 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - XFOR
X4 Pharmaceuticals is a biopharmaceutical company focused on treating rare diseases associated with dysfunction of the chemokine receptor CXCR4. It has one approved drug. The chart shows how investors assess the commercial potential of this drug for a very specific patient group and its future development.
P/S market segment - Pharma immune
X4 Pharmaceuticals, Inc. is a late-stage clinical development biopharmaceutical company focused on treating rare immune system disorders. Its lead drug targets WHIM syndrome. This chart shows the average valuation in the sector, allowing one to assess the market's perception of X4's revenue potential.
P/S of the market as a whole
X4 Pharmaceuticals develops drugs for the treatment of rare immunodeficiency and oncological diseases by targeting the CXCR4 receptor. The company is in late-stage clinical trials. This chart, reflecting the average estimated real revenue, clearly highlights how biotech investments are betting on scientific breakthroughs in orphan diseases.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company XFOR
X4 Pharmaceuticals develops drugs to treat rare immune diseases and oncology. This chart shows how investors assess the future commercial potential of its lead drug. This assessment is based on expectations for its approval and sales for the treatment of patients with rare primary immunodeficiencies.
%20P%2FS%20XFOR&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-XFOR&v=1772545620809 "The graph of the company's future (projected) P/S XFOR")
Future (projected) P/S of the market segment - Pharma immune
X4 Pharmaceuticals is a biopharmaceutical company developing oral therapies for rare immunodeficiency diseases and oncology by targeting the CXCR4 receptor. The chart shows how investors estimate X4's future sales, reflecting the potential of its targeted therapy for patients with limited treatment options.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772545620975 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
Investor optimism about future earnings depends on progress in treating rare immune diseases. X4 Pharmaceuticals is developing drugs for patients with congenital immunodeficiencies. Their work in this complex area of genetics offers hope that new, effective treatments will become available for people with rare diseases.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772545620993 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales XFOR
X4 Pharmaceuticals is a late-stage biopharmaceutical company focused on treating rare immune system diseases. Currently, its revenue is generated not from sales but from payments under collaboration agreements. This chart reflects its path to potential commercialization of its first drug.
Sales of companies in the market segment - Pharma immune
X4 Pharmaceuticals is a biopharmaceutical company developing oral therapies for the treatment of rare immunodeficiency diseases and oncology. This chart reflects the company's overall revenue in the immunology pharmaceutical sector. It illustrates the importance of developing drugs for patients with orphan diseases, who often have no other treatment options.
Overall market sales
X4 Pharmaceuticals is a biopharmaceutical company developing oral therapies for rare immunodeficiency and oncology diseases. Its lead candidate targets WHIM syndrome. Success depends on regulatory approval and commercialization. This overall economics impact the company through the availability of capital for R&D and healthcare budgets for rare diseases.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company XFOR
X4 Pharmaceuticals develops drugs to treat rare immune and hematological diseases by blocking the CXCR4 receptor. The company has one drug in late-stage development. The future depends on its approval. The chart shows analysts' speculative revenue forecasts, which are a bet on the drug's commercial success.
%20sales%20of%20the%20company%20XFOR&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-XFOR&v=1772545621257 "Schedule of future (projected) sales of the company XFOR")
Future (projected) sales of companies in the market segment - Pharma immune
X4 Pharmaceuticals is a biopharmaceutical company focused on treating rare immune deficiency diseases and certain cancers by inhibiting the CXCR4 receptor. Success depends on clinical data. This chart displays projected sales for the entire immunology pharmaceuticals segment, highlighting overall growth expectations for this cutting-edge medical field.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772545621264 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
X4 Pharmaceuticals is a biopharmaceutical company developing drugs to treat rare immune and oncological diseases. The company has an approved product and continues research. This overall economic activity schedule impacts healthcare system budgets, which determine demand for expensive drugs to treat orphan diseases.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772545621333 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality XFOR
X4 Pharmaceuticals is a biotech company developing drugs to treat rare immune diseases. This metric reflects its path to commercialization. It demonstrates how successfully the company converts revenue from its first approved drug into net profit, covering marketing and research costs.
Market segment marginality - Pharma immune
X4 Pharmaceuticals is a biopharmaceutical company developing drugs to treat rare immune diseases. Being in the clinical stage, its financial metrics reflect its investment in R&D. This chart provides an overview of the company's operating model and cost structure compared to other companies in its niche.
Market marginality as a whole
X4 Pharmaceuticals is a late-stage biopharmaceutical company developing drugs for the treatment of rare immune diseases. Their lead candidate is for the treatment of WHIM syndrome. Their future depends on regulatory approval. This gross margin schedule does not affect their operations, which are driven by medical need and scientific data.
Employees in the company, segment and market as a whole
Number of employees in the company XFOR
X4 Pharmaceuticals is a biotech company developing drugs to treat rare immune system diseases. While in the clinical stage, it has a compact team. This chart shows the dynamics of the team of scientists and clinical development specialists focused on advancing its lead drug candidate.
Share of the company's employees XFOR within the market segment - Pharma immune
X4 Pharmaceuticals develops drugs to treat rare diseases associated with dysfunction of the chemokine receptor CXCR4. This chart shows the concentration of unique immunologists and hematologists. The proportion of these specialists reflects its leadership in targeting this specific signaling pathway.
Number of employees in the market segment - Pharma immune
X4 Pharmaceuticals, Inc. is a late-stage biopharmaceutical company developing drugs to treat rare diseases related to the immune system. This chart shows the overall employment in the immunology research sector. It illustrates the company's focus on orphan diseases with high unmet medical needs.
Number of employees in the market as a whole
X4 Pharmaceuticals is a biotech company developing therapies for rare immune and oncological diseases associated with dysfunction of the chemokine receptor CXCR4. This chart illustrates the labor market, where specialized biotech companies like X4 are creating demand for highly qualified immunologists, oncologists, and rare disease specialists.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company XFOR (XFOR)
X4 Pharmaceuticals, Inc. is a biopharmaceutical company developing drugs to treat rare immune and oncological diseases. This chart is a prime example of biotech. The very high market capitalization per employee shows that investors are focusing on the potential of unique orphan drugs rather than on current operating metrics.
%20of%20the%20company%20XFOR%20(XFOR)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-XFOR-XFOR&v=1772545621976 "Chart of market capitalization per employee (in thousands of dollars) of the company XFOR (XFOR)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
X4 Pharmaceuticals is a biotech company focused on treating rare diseases related to the immune system. Their value is determined by the potential of their drug candidates. This metric reflects the value the market places on their research. A high value reflects investors' bet on the success of their targeted therapy.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772545622102 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
X4 Pharmaceuticals is a clinical-stage biopharmaceutical company focused on treating rare immune diseases. Its valuation is dependent on the success of its lead drug. This metric illustrates how the market values companies targeting orphan diseases, where drug prices are high but the patient population is small.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772545622185 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company XFOR (XFOR)
X4 Pharmaceuticals (XFOR) is a biotech company with both an approved drug for rare immune diseases and an R&D pipeline. It operates under a hybrid model. This chart shows the net balance between commercial revenue and research expenses per employee.
%20Chart%20XFOR%20(XFOR)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-XFOR-XFOR&v=1772545622240 "Company Profit Per Employee (in thousands of dollars) Chart XFOR (XFOR)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
X4 Pharmaceuticals is a clinical-stage biotech focused on treating rare diseases. Like most biotechs in the R&D phase, this metric is currently negative. This chart provides a guide to the future. Success will depend on whether their scientific team can develop a drug that delivers profitability above the industry standard.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772545622274 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
X4 Pharmaceuticals (XFOR) is a biotech company developing treatments for rare immune system diseases. Like many companies at this stage, their focus is on science and clinical trials, not sales. This metric reflects capital burn: each scientist employed is an investment, leading to negative returns until the drug is approved.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772545622423 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee XFOR (XFOR)
This chart for X4 Pharmaceuticals, a company developing drugs to treat rare immune diseases, shows progress in commercialization. Revenue per employee growth will depend on the successful launch of its lead drug candidate.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-XFOR-XFOR&v=1772545622462 "Sales chart per company employee XFOR (XFOR)")
Sales per employee in the market segment - Pharma immune
X4 Pharmaceuticals is a biopharmaceutical company focused on treating rare immune diseases. Their core business is R&D and clinical trials. This metric reflects the average revenue per employee for the segment. It allows us to assess how productive X4's R&D team is in advancing its drugs compared to other biotech companies in the immunology sector.
Sales per employee for the market as a whole
X4 Pharmaceuticals (XFOR) is a biopharmaceutical company focused on treating rare immune diseases. They have both an approved drug and an R&D pipeline. This metric reflects their hybrid model. The growth in revenue per employee reflects the successful launch and sales of their first drug, which funds further development.
Short shares by company, segment and market as a whole
Shares shorted by company XFOR (XFOR)
X4 Pharmaceuticals is a biotech company focused on treating rare immune diseases. Its success hinges on a single lead drug. This chart reflects investor bets that the drug will not be approved or, if approved, that its commercial launch will fail due to a very small and difficult-to-reach patient market.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-XFOR-XFOR&v=1772545622726 "Short Shares Chart for the Company XFOR (XFOR)")
Shares shorted by market segment - Pharma immune
X4 Pharmaceuticals (XFOR) is a biopharmaceutical company developing drugs to treat rare immune system diseases by targeting the CXCR4 pathway. This chart shows the overall short position in the rare disease biotech sector. It reflects the high risk and failure rate associated with drug development for these complex conditions.
Shares shorted by the overall market
X4 Pharmaceuticals develops treatments for rare immune diseases. This is a very narrow and risky biotech niche. This chart shows the rise in general investor fear. At such times, liquidity drains from the market, and companies like X4, which need significant capital for long-term clinical trials, are the first to be sold off.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator XFOR (XFOR)
This chart for X4 Pharmaceuticals reflects binary bets on rare disease treatments. The company develops therapies for patients with immune system disorders. When X4 releases positive trial data, investors see the potential for a monopoly in a niche market, leading to overheating (above 70). Any regulatory hurdles or doubts about efficacy lead to immediate panic and oversold conditions (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-XFOR-XFOR&v=1772545622936 "RSI 14 indicator chart for the company's stock XFOR (XFOR)")
RSI 14 Market Segment - Pharma immune
X4 Pharma (XFOR) is a biotech company focused on rare immune diseases (WHIM syndrome). The Pharma-immune (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It's vital to understand whether XFOR's growth is due to its R&D or whether the entire biotech sector is simply overheated by expectations.
RSI 14 for the overall market
X4 Pharmaceuticals (XFOR) is a biotech R&D company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast XFOR (XFOR)
X4 Pharmaceuticals is a biotech company focused on treating rare immune system disorders, primarily WHIM syndrome. This chart shows the speculative average price target from analysts, which is almost entirely dependent on their assessment of clinical trial success.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-XFOR-XFOR&v=1772545623223 "A chart showing analyst consensus forecasts for the expected stock price. XFOR (XFOR)")
The difference between the consensus estimate and the actual stock price XFOR (XFOR)
X4 Pharmaceuticals (XFOR) is a biopharmaceutical company whose first drug (Mavorixafor) was approved for the treatment of a rare immune disorder (WHIM). This chart is a barometer of their commercialization. It measures the gap between the price and the consensus target, reflecting the potential analysts see in their orphan drug.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-XFOR-XFOR&v=1772545623344 "A chart showing the difference between the consensus forecast and the actual stock price. XFOR (XFOR)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
X4 Pharmaceuticals (XFOR) is a biotech company specializing in the treatment of rare immune diseases, such as WHIM syndrome. This chart shows analysts' overall expectations for the immunotherapy sector. It reflects whether experts believe in the commercial potential of drugs for "ultra-orphan" diseases.
Analysts' consensus forecast for the overall market share price
X4 Pharmaceuticals is a biotech company specializing in the treatment of rare immune diseases (WHIM syndrome) by targeting the CXCR4 receptor. This chart shows the overall risk appetite. For X4, a clinical-stage company with a niche focus, overall market optimism is important for raising the capital needed to fund R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index XFOR
X4 Pharma is a biotech company focused on treating rare immune diseases. Their flagship product (Mavorixafor) is targeted at patients with rare forms of neutropenia (immune cell deficiency). This chart is a summary indicator of their commercialization, reflecting their R&D progress and their ability to bring this orphan drug to market.
AKIMA Market Segment Index - Pharma immune
X4 Pharmaceuticals (XFOR) is a biopharmaceutical company specializing in the treatment of rare immunodeficiency diseases, specifically WHIM syndrome. Their approach is based on CXCR4 receptor inhibition. The chart shows the segment average index, allowing investors to assess how X4's risks and potential in the rare disease niche compare to the average in the immunopharmaceutical sector.
The AKIM Index for the overall market
X4 Pharmaceuticals is a biotech company commercializing Xolremdi, a drug for the treatment of a rare immunodeficiency disorder (WHIM syndrome). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this company, launching its first product, compares to the overall economic trends in the rare disease sector.
